IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer

Overview

Journal J Oncol

Specialty Oncology

Date 2022 May 9

PMID 35528245

Authors

Guangyao Li

Yandong Wang

Ya Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin-2 receptor (IL2RB) is a receptor protein of interleukin-2. IL2RB is implicated in regulation of T cell-mediated immune response. However, the role of IL2RB in pan-cancer is unknown. The present premise sought to explore the role of IL2RB in tumorigenesis, tumor metabolism, and tumor immunity in pan-cancer.

Methods: Data were retrieved from multiple data resources including GTEx data resource, CCLE data resource, TCGA data resource, UCSC data resource, and TISIDB web server. These data were adopted to assess the expression, prognosis value, relationship between IL2RB and immune microenvironment, microsatellite instability, immune new antigen, gene mutation, immune modulatory factors immune checkpoint and TMB, and immune or molecular subtypes of IL2RB in various tumors. Estimate analysis and GSEA were conducted to assess the role of IL2RB in pan-cancer.

Results: Differential analysis illustrated that L2RB was remarkably elevated in pan-cancer, notably in solid tumors compared with normal tissues. Survival analysis indicated that IL2RB was linked to pan-cancer prognosis, and elevated IL2RB contents were remarkably linked to dismal prognosis patients in diverse kinds of cancers. The findings illustrated that IL2RB contents were remarkably linked to tumor immune invasion, tumor microenvironment, TMB, MSI, DNA repair genes, methyl transferases, immune modulatory factors, and immune or molecular subtypes in pan-cancer. IL2RB gene mutation was evident in numerous cancers. The data illustrated that IL2RB contents were remarkably enriched in multiple signaling cascades which modulate tumorigenesis, tumor metabolism along with immunity.

Conclusion: The findings of the present premise illustrate that IL2RB plays an indispensible role in tumorigenesis, tumor metabolism, and immunity. Therefore, it is a prospective target gene in tumor-target therapy and tumor immune therapy. IL2RB is also a valuable predictive biomarker in most solid tumors.

Citing Articles

Integrated bioinformatics analysis of the effects of chronic pain on patients with spinal cord injury.

Zhang J, Qi L, Sun Y, Chen S, Liu J, Chen J Front Cell Neurosci. 2025; 19:1457740.

PMID: 39974584 PMC: 11835904. DOI: 10.3389/fncel.2025.1457740.

Machine Learning Gene Signature to Metastatic ccRCC Based on ceRNA Network.

Farias E, Terrematte P, Stransky B Int J Mol Sci. 2024; 25(8).

PMID: 38673800 PMC: 11049832. DOI: 10.3390/ijms25084214.

M1 macrophage-related gene model for NSCLC immunotherapy response prediction.

Wu S, Sheng Q, Liu P, Jiao Z, Lv J, Qiao R Acta Biochim Biophys Sin (Shanghai). 2024; 56(3):379-392.

PMID: 38379417 PMC: 10984861. DOI: 10.3724/abbs.2023262.

Retracted: IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer.

Oncology J J Oncol. 2023; 2023:9807856.

PMID: 37946722 PMC: 10632053. DOI: 10.1155/2023/9807856.

Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma.

Hu P, Wang Y, Chen X, Zhao L, Qi C, Jiang G Transl Cancer Res. 2023; 12(8):1963-1979.

PMID: 37701111 PMC: 10493807. DOI: 10.21037/tcr-23-61.

References

Wang H, Liu B, Wei J . Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. Cancer Lett. 2021; 517:96-104. DOI: 10.1016/j.canlet.2021.06.008. View

Jia Z, Zhang Z, Yang Q, Deng C, Li D, Ren L . Effect of IL2RA and IL2RB gene polymorphisms on lung cancer risk. Int Immunopharmacol. 2019; 74:105716. DOI: 10.1016/j.intimp.2019.105716. View

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

Xu C, Zang Y, Zhao Y, Cui W, Zhang H, Zhu Y . Comprehensive Pan-Cancer Analysis Confirmed That ATG5 Promoted the Maintenance of Tumor Metabolism and the Occurrence of Tumor Immune Escape. Front Oncol. 2021; 11:652211. PMC: 8027486. DOI: 10.3389/fonc.2021.652211. View

Starzer A, Berghoff A . New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020; 4(Suppl 3):e000629. PMC: 7082637. DOI: 10.1136/esmoopen-2019-000629. View

Cavanillas M, Alcina A, Nunez C, de Las Heras V, Fernandez-Arquero M, Bartolome M . Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet. 2010; 18(7):794-9. PMC: 2987360. DOI: 10.1038/ejhg.2010.15. View

Woo S, Turnis M, Goldberg M, Bankoti J, Selby M, Nirschl C . Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2011; 72(4):917-27. PMC: 3288154. DOI: 10.1158/0008-5472.CAN-11-1620. View

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

Bouzid D, Amouri A, Fourati H, Marques I, Abida O, Tahri N . Polymorphisms in the IL2RA and IL2RB genes in inflammatory bowel disease risk. Genet Test Mol Biomarkers. 2013; 17(11):833-9. DOI: 10.1089/gtmb.2013.0291. View

10.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

11.

Zhang Z, Gothe F, Pennamen P, James J, McDonald D, Mata C . Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance. J Exp Med. 2019; 216(6):1311-1327. PMC: 6547869. DOI: 10.1084/jem.20182304. View

12.

Fernandez I, Baxter R, Garcia-Perez J, Vendrame E, Ranganath T, Kong D . A novel human mutation results in T and NK cell-driven immune dysregulation. J Exp Med. 2019; 216(6):1255-1267. PMC: 6547857. DOI: 10.1084/jem.20182015. View

13.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

14.

Blake S, Dougall W, Miles J, Teng M, Smyth M . Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016; 22(21):5183-5188. DOI: 10.1158/1078-0432.CCR-16-0933. View

15.

Alderdice M, Craig S, Humphries M, Gilmore A, Johnston N, Bingham V . Evolutionary genetic algorithm identifies as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genom Bioinform. 2021; 3(2):lqab016. PMC: 8057496. DOI: 10.1093/nargab/lqab016. View

16.

Pitt J, Marabelle A, Eggermont A, Soria J, Kroemer G, Zitvogel L . Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016; 27(8):1482-92. DOI: 10.1093/annonc/mdw168. View

17.

Durda P, Sabourin J, Lange E, Nalls M, Mychaleckyj J, Jenny N . Plasma Levels of Soluble Interleukin-2 Receptor α: Associations With Clinical Cardiovascular Events and Genome-Wide Association Scan. Arterioscler Thromb Vasc Biol. 2015; 35(10):2246-53. PMC: 5395092. DOI: 10.1161/ATVBAHA.115.305289. View

18.

Korbecki J, Kojder K, Siminska D, Bohatyrewicz R, Gutowska I, Chlubek D . CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020; 21(21). PMC: 7665155. DOI: 10.3390/ijms21218412. View

19.

Valle-Mendiola A, Gutierrez-Hoya A, Lagunas-Cruz M, Weiss-Steider B, Soto-Cruz I . Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer. Mediators Inflamm. 2016; 2016:2849523. PMC: 4880719. DOI: 10.1155/2016/2849523. View

20.

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger M, Soni S . CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2017; 63:40-47. PMC: 5801162. DOI: 10.1016/j.ctrv.2017.11.007. View